W.O.M. WORLD OF MEDICINE AG
W.O.M. World of Medicine english
WORLD OF MEDICINE receives FDA approval for U100 laser
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
WORLD OF MEDICINE receives FDA approval earlier than expected to market its
U100 laser for lithotripsy in the US Sales activities can begin in the world’s
largest medical equipment market.
The medical equipment manufacturer W.O.M. WORLD OF MEDICINE AG received the
approval of the US Food and Drug Administration (FDA) to market its patented
lithotripsy laser U100 for the safe and efficient intracorporal treatment of
kidney, ureter and bladder stones.
Again, the company has underscored its high level of competence in obtaining
the FDA s approval for medical technology devices.
The FDA approval gives WORLD OF MEDICINE access to the second half of the world
market for stone treatment with a conservatively estimated total value of EURO
155 Mio . (2001).
According to analyst’s estimates there are currently 405 Extracorporeal
Shockwave Lithotripters (ESWL) in use in the USA. According to WORLD OF
MEDICINE the relative efficiency and low cost of the laser compared to the
conventional ESWL systems will make it equally attractive to a wide market
including hospitals, small clinics and private urology practices.
Sales are planned to commence in 2002 and will be directed from the company’s
US subsidiary WORLD OF MEDICINE USA, Inc. in Orlando/Florida, which has been in
operation since 1998.
(Berlin, 22. October, 2001)
The board of directors
Further information:
W.O.M. WORLD OF MEDICINE AG, Stefanie Gehrke (IR/PR), eMail:
stefanie.gehrke@womcorp.com,
Phone: 0049 (030) 399 81 566, Fax: 0049 (030) 399 81 605,
Internet: http://www.world-of-medicine.com
end of ad-hoc-announcement (c)DGAP 22.10.2001
Issuer’s information/explanatory remarks concerning this ad-hoc-announcement:
New Milestone reached: WORLD OF MEDICINE receives FDA approval earlier than
expected to market its U100 laser for lithotripsy in the US Sales activities
can begin in the world s largest medical equipment market./
Patented FREDDY-technology enables easy and safe removal of kidney and ureter
stones/
(Berlin, Oktober 22, 2001). Yesterday, the medical equipment manufacturer
W.O.M. WORLD OF MEDICINE AG received the approval of the US Food and Drug
Administration (FDA) to market its patented lithotripsy laser U100 for the safe
and efficient intracorporal treatment of kidney, ureter and bladder stones in
the US. Again, the company has underscored its high competence in the area of
obtaining FDA approvals for medical technology devices.
The FDA approval gives WORLD OF MEDICINE access to the second half of the world
market for stone treatment with a conservatively estimated total value of EURO
155 Mio . (2001).
Sales activities can now begin in the world s largest medical equipment market.
First sales of the laser are planned in 2002.
“We have excellent perspectives for our unique FREDDY-technology in the United
States”, says Peter P. Wiest, founder of the company and CEO of WORLD OF
MEDICINE. “Our laser is safe, very efficient and gentle on the patient.
Moreover, the treatment is less expensive, because for the past 15 years in the
US, procedures have been charged on the a case lump sum basis. Our laser will
render patients stone-free in a single treatment session. Today, most stones
are treated with Extracorporal Shock Wave Lithotripsy (ESWL) but their removal
with this method often requires several treatment sessions. Longer hospital
stays result in higher costs for the patient and/or their insurers and in terms
of days of work lost. Therefore the laser is of real economic valuee to both
the patient and the healthcare system.”
According to analyst’s estimates there are currently 405 Extracorporal
Shockwave Lithotripters (ESWL) in use in the USA. According to WORLD OF
MEDICINE the relative efficiency and low cost of the laser compared to the
conventional ESWL systems will make it equally attractive to a wide market
including hospitals, small clinics and private urology practices. Sales will be
directed from the company’s US subsidiary WORLD OF MEDICINE USA, Inc. in
Orlando/Florida, which has been in operation since 1998.
WORLD OF MEDICINE and its technology are considered paving the way for
innovative procedures in the area of minimally invasive surgery. The
commercial success of the new laser will contribute to the growth of the
company in the coming years. In their lifetime 12% of the US-population suffer
from kidney stones. This translates into about 200.000 acute cases requiring
treatment each year. The laser has already been sold to clinics and dealers in
10 countries in Europe and Asia.
The W.O.M. WORLD OF MEDICINE AG group of companies currently comprises
subsidiaries in Berlin, Ludwigsstadt/Oberfranken, Gröbenzell/Munich as well as
Orlando/USA. It s staff of about 275 are structured into three business sectors
that all focus on minimally invasive surgery: Flow&FluidWORLD (fluid pumps,
insufflators, accessories), LaserWORLD (lasers for MIS) and VisionWORLD
(cameras, monitors, light sources, image editing systems). Sales last year
amounted to approximately 23.6 mio. EURO. In 2001 the company expects this
figure to grow to 33.6 mio. EURO.
Weitere Information: W.O.M. World of Medicine AG, Stefanie Gehrke (IR/PR),
eMail: stefanie.gehrke@womcorp.com,
Phone: 0049 (030) 399 81 566, Fax: 0049 (030) 399 81 605,
Internet: http://www.world-of-medicine.com
——————————————————————————–
WKN: 663739; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München, Stuttgart
220949 Okt 01
Latest News
Latest Reports
Upcoming Events
No Events found